The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
Open accessAbstract
Objective: To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with moderate‐to‐severe systemic lupus erythematosus (SLE). Methods: Patients (n = 305) were randomized to receive intravenous anifrolumab (300 mg or 1,000 mg) or placebo, in addition to standard therapy, every 4 weeks for 48 weeks. Randomization was stratified by SLE Disease Activity Index 2000 score (<10 or ≥10), oral corticosteroid dosage (<10 or ≥10 mg/day), and type I IFN gene signature test status (high or low) based on a 4‐gene expression assay. The primary end point was the percentage of patients achieving an SLE Responder Index (SRI[4]) response at week 24 with sustained reduction of oral corticosteroids (<10 mg/day and less than or equal to the dose at week 1 from week 12 through 24). Other end points (including SRI[4], British Isles Lupus Assessment Group [BILAG]–based Composite Lupus Assessment [BICLA], modified SRI[6], and major clinical response) were assessed at week 52. The primary end point was analyzed in the modified intent‐to‐treat (ITT) population and type I IFN–high subpopulation. The study result was considered positive if the primary end point was met in either of the 2 study populations. The Type I error rate was controlled at 0.10 (2‐sided), within each of the 2 study populations for the primary end point analysis. Results: The primary end point was met by more patients treated with anifrolumab (34.3% of 99 for 300 mg and 28.8% of 104 for 1,000 mg) than placebo (17.6% of 102) ( P = 0.014 for 300 mg and P = 0.063 for 1,000 mg, versus placebo), with greater effect size in patients with a high IFN signature at baseline (13.2% in placebo‐treated patients versus 36.0% [ P = 0.004] and 28.2% [ P = 0.029]) in patients treated with anifrolumab 300 mg and 1,000 mg, respectively. At week 52, patients treated with anifrolumab achieved greater responses in SRI(4) (40.2% versus 62.6% [ P < 0.001] and 53.8% [ P = 0.043] with placebo, anifrolumab 300 mg, and anifrolumab 1,000 mg, respectively), BICLA (25.7% versus 53.5% [ P < 0.001] and 41.2% [ P = 0.018], respectively), modified SRI(6) (28.4% versus 49.5% [ P = 0.002] and 44.7% [ P = 0.015], respectively), major clinical response (BILAG 2004 C or better in all organ domains from week 24 through week 52) (6.9% versus 19.2% [ P = 0.012] and 17.3% [ P = 0.025], respectively), and several other global and organ‐specific end points. Herpes zoster was more frequent in the anifrolumab‐treated patients (2.0% with placebo treatment versus 5.1% and 9.5% with anifrolumab 300 mg and 1,000 mg, respectively), as were cases reported as influenza (2.0% versus 6.1% and 7.6%, respectively), in the anifrolumab treatment groups. Incidence of serious adverse events was similar between groups (18.8% versus 16.2% and 17.1%, respectively). Conclusion: Anifrolumab substantially reduced disease activity compared with placebo across multiple clinical end points in the patients with moderate‐to‐severe SLE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297
SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX
(2007) · Systemic Lupus Erythematosus · doi:10.1016/b978-0-323-04434-9.50060-9 · Cited by 2,928
Mortality in systemic lupus erythematosus
Bernatsky, S., Boivin, J. ‐., Joseph, L., Manzi, S., Ginzler, E., Gladman, D. D., Urowitz, M., Fortin, P. R., Petri, M., Barr, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21955 · Cited by 1,181
Systemic Lupus Erythematosus Disease Activity Index
National Cancer Institute (2020) · Definitions · doi:10.32388/n5g0vc · Cited by 1,003
Isenberg, D. A., Rahman, A., Allen, E., Farewell, V., Akil, M., Bruce, I. N., D'Cruz, D., Griffiths, B., Khamashta, M., Maddison, P., et al. (2005) · Rheumatology · doi:10.1093/rheumatology/keh624 · Cited by 636
Self-citationType I Interferon in the Pathogenesis of Lupus
Crow, M. K. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1002795 · Cited by 561
Albrecht, J., Taylor, L., Berlin, J. A., Dulay, S., Ang, G., Fakharzadeh, S., Kantor, J., Kim, E., Militello, G., McGinnis, K., et al. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23889.x · Cited by 510
Self-citationKhamashta, M., Merrill, J. T., Werth, V. P., Furie, R., Kalunian, K., Illei, G. G., Drappa, J., Wang, L., & Greth, W. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208562 · Cited by 503
Self-citation
Cited by
Kaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz-Irastorza, G., & Hughes, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.39 · Cited by 1,391
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Morand, E. F., Furie, R., Tanaka, Y., Bruce, I. N., Askanase, A. D., Richez, C., Bae, S.-C., Brohawn, P. Z., Pineda, L., Berglind, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912196 · Cited by 1,379
Self-citationSystemic lupus erythematosus: Diagnosis and clinical management
Fava, A., & Petri, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.11.001 · Cited by 754
The dual nature of type I and type II interferons
Lee, A. J., & Ashkar, A. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02061 · Cited by 690
Management strategies and future directions for systemic lupus erythematosus in adults
Durcan, L., O'Dwyer, T., & Petri, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30237-5 · Cited by 648
IRF3 and type I interferons fuel a fatal response to myocardial infarction
King, K. R., Aguirre, A. D., Ye, Y.-X., Sun, Y., Roh, J. D., Ng, R. P., Kohler, R. H., Arlauckas, S. P., Iwamoto, Y., Savol, A., et al. (2017) · Nature Medicine · doi:10.1038/nm.4428 · Cited by 570
Novel paradigms in systemic lupus erythematosus
Dörner, T., & Furie, R. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30546-x · Cited by 565
Self-citationInterferon target-gene expression and epigenomic signatures in health and disease
Barrat, F. J., Crow, M. K., & Ivashkiv, L. B. (2019) · Nature Immunology · doi:10.1038/s41590-019-0466-2 · Cited by 530
Wallace, D. J., Furie, R. A., Tanaka, Y., Kalunian, K. C., Mosca, M., Petri, M. A., Dörner, T., Cardiel, M. H., Bruce, I. N., Gomez, E., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31363-1 · Cited by 513
Self-citationFurie, R. A., Morand, E. F., Bruce, I. N., Manzi, S., Kalunian, K. C., Vital, E. M., Lawrence Ford, T., Gupta, R., Hiepe, F., Santiago, M., et al. (2019) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30076-1 · Cited by 512
Self-citationNeuropsychiatric lupus: new mechanistic insights and future treatment directions
Schwartz, N., Stock, A. D., & Putterman, C. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0156-8 · Cited by 429
Baker, K. F., & Isaacs, J. D. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211555 · Cited by 370
Regulating IRFs in IFN Driven Disease
Jefferies, C. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00325 · Cited by 365
van Vollenhoven, R. F., Hahn, B. H., Tsokos, G. C., Wagner, C. L., Lipsky, P., Touma, Z., Werth, V. P., Gordon, R. M., Zhou, B., Hsu, B., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32167-6 · Cited by 330
Self-citationType I interferon in rheumatic diseases
Muskardin, T. L. W., & Niewold, T. B. (2018) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2018.31 · Cited by 308
Kato, Y., Park, J., Takamatsu, H., Konaka, H., Aoki, W., Aburaya, S., Ueda, M., Nishide, M., Koyama, S., Hayama, Y., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-212988 · Cited by 304
The Role of Epigenetics in Autoimmune/Inflammatory Disease
Surace, A. E. A., & Hedrich, C. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01525 · Cited by 302
Type I Interferons in Autoimmune Disease
Crow, M. K., Olferiev, M., & Kirou, K. A. (2019) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043952 · Cited by 291
Burke, J. R., Cheng, L., Gillooly, K. M., Strnad, J., Zupa-Fernandez, A., Catlett, I. M., Zhang, Y., Heimrich, E. M., McIntyre, K. W., Cunningham, M. D., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw1736 · Cited by 289
Neutrophil Extracellular Traps (NETs) Take the Central Stage in Driving Autoimmune Responses
Fousert, E., Toes, R., & Desai, J. (2020) · Cells · doi:10.3390/cells9040915 · Cited by 282
Sarkar, M. K., Hile, G. A., Tsoi, L. C., Xing, X., Liu, J., Liang, Y., Berthier, C. C., Swindell, W. R., Patrick, M. T., Shao, S., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213197 · Cited by 279
Fresneda Alarcon, M., McLaren, Z., & Wright, H. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.649693 · Cited by 278
Smolen, J. S., Genovese, M. C., Takeuchi, T., Hyslop, D. L., Macias, W. L., Rooney, T., Chen, L., Dickson, C. L., Riddle Camp, J., Cardillo, T. E., et al. (2019) · The Journal of Rheumatology · doi:10.3899/jrheum.171361 · Cited by 258
Microglia-dependent synapse loss in type I interferon-mediated lupus
Bialas, A. R., Presumey, J., Das, A., van der Poel, C. E., Lapchak, P. H., Mesin, L., Victora, G., Tsokos, G. C., Mawrin, C., Herbst, R., et al. (2017) · Nature · doi:10.1038/nature22821 · Cited by 197
RetractedGong, K., Guo, G., Panchani, N., Bender, M. E., Gerber, D. E., Minna, J. D., Fattah, F., Gao, B., Peyton, M., Kernstine, K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0048-0 · Cited by 92
Carter, V., LaCava, J., Taylor, M. S., Liang, S. Y., Mustelin, C., Ukadike, K. C., Bengtsson, A., Lood, C., & Mustelin, T. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41054 · Cited by 41
Antiphospholipid syndrome: an update for clinicians and scientists
Vreede, A. P., Bockenstedt, P. L., & Knight, J. S. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000410 · Cited by 22
Metadata
- Authors
- Furie, R., Khamashta, M., Merrill, J. T., Werth, V. P., Kalunian, K., Brohawn, P., Illei, G. G., Drappa, J., Wang, L., Yoo, S., & for the CD1013 Study Investigators
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2017-01-28
- Volume
- 69
- Issue
- 2
- Pages
- 376-386
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W2556359407
- Cited by
- 882
- References
- 29
- FWCI
- 88.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.